Browsing: RLY2608

Treatments

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)

By 0

BackgroundPIK3CA mutations constitutively activate PI3Kα and drive approximately40% of hormone receptor–positive (HR+)/HER2-negative (HER2–) breast cancer. The PI3K inhibitors (i) alpelisib…